BONESUPPORT HOLDING AB (PUBL) INTERIM REPORT JANUARY – JUNE 2026

Q2 2026

Net sales: SEK 355.7 m (284.4)

Growth at constant exchange rates: 30%

Adjusted operating result: SEK 104.1 m (62.4)

Gross margin: 90.8% (92.3)

THE QUARTER IN BRIEF

APRIL - JUNE 2026

- Net sales increased by 25 percent (30 percent at constant exchange rates[1]) and amounted to SEK 355.7 million (284.4).
- The US segment reported a sales growth of 25 percent (31 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 24 percent (26 percent at constant exchange rates).
- The gross margin amounted to 90.8 percent (92.3).
- The adjusted operating result[1] amounted to SEK 104.1 million (62.4). The reported operating result amounted to SEK 89.6 million (54.9).
- Earnings per share before dilution were SEK 1.24 (0.81).
- Earnings per share after dilution were SEK 1.23 (0.79).

JANUARY - JUNE 2026

- Net sales increased by 20 percent (31 percent at constant exchange rates[1]) and amounted to SEK 679.7 million (568.0).
- The US segment reported a sales growth of 20 percent (33 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 16 percent (21 percent at constant exchange rates).
- The gross margin amounted to 91.5 percent (92.5).
- The adjusted operating result[1] amounted to SEK 189.0 million (102.1). The reported operating result amounted to SEK 161.7 million (84.5).
- Earnings per share before dilution were SEK 2.05 (0.96).
- Earnings per share after dilution were SEK 2.03 (0.95).

EVENTS DURING THE QUARTER

- In April, the US Centers for Medicare & Medicaid Services (CMS) published its proposed rule for the Medicare Inpatient Prospective Payment System (IPPS) for the fiscal year 2027. The proposal includes changes that improve payments for the use of CERAMENT G in the treatment of complex orthopedic infections, such as periprosthetic joint infection (PJI), fracture related infections, and diabetes related bone infection (diabetic foot). Final ruling is expected towards the end of the summer.
- In May, the Company published its VSME Sustainability report for 2025.
- In May, the Company hosted a Capital Markets Day for analysts, investors and media.
- In June, the Company repurchased 373,320 own ordinary shares in agreement with a decision by the Annual General meeting on May 12, 2026. The buy-back program was carried out for the purpose of ensuring the Company's obligations arising from the long-term share savings program LTI 2026 resolved by the Annual General Meeting on May 12, 2026.

EVENTS AFTER THE QUARTER

- Adjustment of the guidance for 2026 to a sales growth of between 33-36 percent in constant exchange rates (previous guidance was a sales growth of more than 35 percent in constant exchange rates).

KEY FIGURES

	Apr - Jun		Jan - Jun		12 months	
	2026	2025	2026	2025	LTM	2025
Net sales, SEKm	355.7	284.4	679.7	568.0	1,286.4	1174.7
Sales growth, %[1]	25.1	29.4	19.7	40.5	21.1	30.7
Gross profit, SEKm	323.0	262.6	621.9	525.1	1,184.1	1087.3
Gross margin, %[1]	90.8	92.3	91.5	92.5	92.0	92.6
Operating result, SEKm	89.6	54.9	161.7	84.5	308.9	231.7
Result for the period, SEKm	81.9	53.1	135.3	63.5	213.9	142.2
Earnings per share before dilution, SEK	1.24	0.81	2.05	0.97	3.25	2.16
Earnings per share after dilution, SEK	1.23	0.79	2.03	0.95	3.20	2.13
Operating cash flows, SEKm	67.1	49.8	142.0	96.5	266.9	221.3
Cash at period end, SEKm	434.3	309.7	434.3	309.7	434.3	378.0
Equity at period end, SEKm	949.7	796.7	949.7	796.7	949.7	867.3
Net cash at period end, SEKm[1]	424.2	297.0	424.2	297.0	424.2	366.3

1 For definitions and calculations of Alternative Performance Measures, see Pages 26-27.

STRONG GROWTH AND IMPROVED OPERATING RESULT

The second quarter shows 30 percent growth in constant currency and an adjusted operating result of SEK 104 million, corresponding to 29 percent operating margin.

Net sales for the quarter amounted to SEK 356 million, corresponding to 25 percent reported growth and 30 percent in constant currency. Growth was somewhat lower than expected. Gross margin amounted to 90.8 percent, impacted by an inventory write-down of SEK 3 million and the introduction of US tariffs. Our pricing discipline remains strong, resulting in stable price levels. Adjusted operating profit amounted to SEK 104 million, corresponding to an operating margin of 29 percent.

Net sales in the US reached SEK 295 million, corresponding to a growth of 31 percent in constant exchange rate, which is slightly lower than expected. The quarter was characterized by some volatility in sales. Recruitment of new customers in the US continued at a high and stable pace in line with previous quarters across all three segments - Foot & Ankle, Trauma, and Arthroplasty.

EUROW grew by 26 percent in constant currency, with strong development across most geographies. The company's model of direct, hybrid, and distributor markets is well suited to the early stage the company is currently in. In Germany, market conditions have stabilized, and healthcare providers have adapted to the "new normal" following last year's market reforms. New markets continue to develop very strongly, and in India we see early-stage utilization in line with expectations.

After a period of significant commercial investment, it is encouraging to see the strong operating margin, together with continued strong cash flows, as confirmation of the scalability of our business model.

The regulatory process for CERAMENT V in the US is proceeding on plan within the De Novo process, in continued constructive dialogue with the FDA. The company is well prepared to respond to requested details and clarifications by the end of August at the latest.

In June, the company executed its first planned share buyback program, repurchasing 373,320 shares for just under SEK 83 million, including commissions. For shareholders, this means their share of the company's future earnings has increased, without any additional capital being required. The company has a mandate to continue repurchasing its own shares.

During the quarter, the company held a Capital Markets Day, where we presented our strategy and long-term ambitions. The main purpose was to help the market understand the business — its strengths, weaknesses, and where we actually allocate capital and why. Long-term owners deserve the same information management uses to make decisions.

A central message at the Capital Markets Day was that significant market potential remains for the CERAMENT platform. Penetration is still low in the more established segments — Foot & Ankle and Trauma — and the Arthroplasty market remains largely unexploited. Our growth strategy is built on continuing to drive awareness, access, and adoption in new and existing hospitals, and broadening use into additional indications, such as spine surgery. We see clear opportunities to increase utilization per user through more structured commercial execution and a continued strong offering based on clinical evidence and health-economic data.

As a result of the first half of the year's sales growth of 31 percent in constant exchange rates, we estimate full-year sales growth to be between 33 and 36 percent in constant exchange rates.

Beyond this, the quarter confirms that the Company's position has strengthened and continues to be characterized by relatively low, but rapidly increasing, market penetration — creating significant room for expansion for many years to come.

Torbjörn Sköld
CEO

FIVE QUARTERS IN BRIEF

NET SALES, SEKM



NET SALES SEGMENT US, USDM



ADJUSTED OPERATING RESULT[1], SEKM



The Group's operations are international and exposed to currency risk, primarily from USD but also from EUR and GBP. Over the past year, large fluctuations have been experienced, especially in USD, which has impacted reported net sales and made it difficult to compare with previous quarters.

The graph Net sales CER[1] (constant currencies) shows a very stable quarterly sales trend, which is also shown by the graph Net sales segment US which is in USD millions.

NET SALES CER[1], SEKM



NET SALES SEGMENT EUROW, SEKM



1 For definitions and calculations of Alternative Performance Measures, see Pages 26-27.

SEGMENT US

The US market is the world's largest for synthetic bone graft products and thus the Company's most important market. CERAMENT BVF and CERAMENT G are commercially available in the United States. BONESUPPORT's own marketing organization in the United States handles sales and distribution through independent distributors.

APRIL - JUNE

Net sales

Net sales for the quarter amounted to SEK 295.2 million (235.6), corresponding to a growth of 25 percent (31 percent in constant exchange rate), which is somewhat lower than expected. The quarter was characterized by some volatility in sales. Recruitment of new customers in the US continued at a high and stable pace in line with previous quarters across all three segments. Sales of CERAMENT G amounted to SEK 243.5 million (178.9) in the quarter.

Contribution[1]

The contribution from the segment was SEK 140.3 million (104.4). The increase in sales contributed to an increased gross profit by SEK 53.8 million compared to the previous year. During the quarter, selling and marketing expenses amounted to SEK 135.3 million (117.8), of which sales commissions to distributors and fees amounted to SEK 94.7 million (78.5), corresponding to 32.0 percent (33.3) of net sales.

JANUARY - JUNE

Net sales amounted to SEK 562.3 million (466.8), corresponding to a growth of 20 percent (33 percent in constant exchange rate).

The contribution from the segment was SEK 263.0 million (201.6).

NET SALES PER QUARTER, SEKM



CONTRIBUTION PER QUARTER, SEKM



NET SALES, GROSS PROFIT AND CONTRIBUTION

	Apr - Jun		Jan - Jun		Full year
SEKm	2026	2025	2026	2025	2025
Net sales	295.2	235.6	562.3	466.8	971.9
Gross profit	276.9	223.1	529.2	442.8	922.9
Contribution	140.2	104.4	262.8	201.6	432.9

1 For definitions and calculations of Alternative Performance Measures, see Pages 26-27.

EUROPE & REST OF THE WORLD (EUROW)

In Europe, CERAMENT is sold by both the Company's own sales organization and distributors. Benelux, Denmark, Germany, Norway, Sweden and the UK are key markets where BONESUPPORT has its own sales representatives. In Australia, Canada, Italy, Spain and South Africa, the Company has established a hybrid model, with qualified local staff from BONESUPPORT working side by side with the local distributors' sales representatives. In other European markets and in other parts of the world (ROW), the Company collaborates with specialist distributors. The focus is on accelerating the sales and use of CERAMENT in established and emerging markets through market advancement and the provision of clinical and health economic evidence.

APRIL - JUNE

Net sales

Net sales for the quarter amounted to SEK 60.5 million (48.8), corresponding to a growth of 24 percent (26 percent in constant exchange rates).

Net sales in key markets accounted for 79 percent (83) of the segment's sales during the quarter. Sales of the antibiotic-eluting products CERAMENT G and CERAMENT V corresponded to 89 percent (90).

Contribution[1]

The contribution from the segment amounted to SEK 16.8 million (13.6). Selling and marketing expenses increased by SEK 5.3 million and amounted to SEK 32.0 million (26.7). The increase is partly due to the marketing investments that have already been communicated and the expense was in line with the most recent quarter.

JANUARY - JUNE

Net sales amounted to SEK 117.4 million (101.1), corresponding to a growth of 16 percent (21 percent in constant exchange rates).

The contribution from the segment amounted to SEK 29.5 million (29.0).

NET SALES PER QUARTER, SEKM



CONTRIBUTION PER QUARTER, SEKM



NET SALES, GROSS PROFIT AND CONTRIBUTION

	Apr - Jun		Jan - Jun		Full year
SEKm	2026	2025	2026	2025	2025
Net sales	60.5	48.8	117.4	101.1	202.8
Gross profit	48.8	40.3	95.4	83.6	166.2
Contribution	16.8	13.6	29.5	29.0	53.3

1 For definitions and calculations of Alternative Performance Measures, see Pages 26-27.

FINANCIAL OVERVIEW – PROFIT AND LOSS

APRIL - JUNE

Net sales
Net sales amounted to SEK 355.7 million (284.4), corresponding to an increase of 25 percent compared to the previous year (30 percent at constant exchange rates).

In the US segment, net sales amounted to SEK 295.2 million (235.6), which corresponds to growth of 25 percent (31 percent at constant exchange rate), which is somewhat lower than expected. The quarter was characterized by some volatility in sales. Recruitment of new customers in the US continued at a high and stable pace in line with previous quarters across all three segments. Sales of CERAMENT G in the quarter amounted to SEK 243.5 million (178.9).

Net sales for the EUROW segment amounted to SEK 60.5 million (48.8), which corresponds to an increase of 24 percent (26 percent at constant exchange rates). The strong growth can be partly explained by a weak comparison quarter during previous year.

NET SALES PER QUARTER, SEKM



Cost of sales
Cost of sales amounted to SEK 32.7 million (21.8), giving a gross margin of 90.8 percent (92.3). The gross margin was burdened by inventory write-downs regarding components and material amounting to SEK 2.7 million, and by American tariffs that were SEK 1.5 million higher than during the same quarter previous year.

Selling expenses including sales commissions and fees
Selling expenses, including sales commissions and fees, amounted to SEK 178.7 million (146.7), corresponding to an increase of 22 percent. This is further detailed in the table below.

As a result of the growth in sales, the US segment reported a cost increase to SEK 135.5 million (117.8) of which its share of sales commissions and fees increased from SEK 78.5 million to SEK 94.7 million. In EUROW, expenses amounted to SEK 32.0 million (26.7). The increase is mainly due to the commercial investments that were made during 2025 in new hybrid markets. Non-allocated costs amounted to SEK 11.3 million (2.2).

SELLING EXPENSES

	Apr - Jun		
SEKm	2026	2026 CER[1]	2025
Sales commissions and fees	95.3	104.8	79.4
Personnel expenses	56.3	60.0	49.5
Other selling expenses	27.2	32.4	17.7
Total selling expenses	**178.7**	**197.2**	**146.7**

1 For definitions and calculations of Alternative Performance Measures, see Pages 26-27.

Research and development expenses
Research and development expenses amounted to SEK 24.8 million (23.6). The item consists of personnel expenses and expenses for the projects focusing on market approval for CERAMENT V, application studies within Spine and the work behind developing the next generation of CERAMENT.

Administrative expenses
Administrative expenses amounted to SEK 34.4 million (26.1).

Administrative expenses excluding effects from the Group's long-term incentive programs amounted to SEK 19.9 million (18.5), of which personnel expenses amounted to SEK 8.0 million (8.0).

Effects regarding the long-term incentive programs amounted to an expense of SEK 14.5 million (7.6). The increase is due to a new program being added since the corresponding quarter previous year, but also to a positive share price development during the quarter.

Other operating income and expenses
Other operating income and expenses consisted mainly of foreign exchange gains and losses, netting to an income of SEK 4.4 million, to compare with an expense of SEK 11.6 million during the corresponding quarter previous year. The gains and losses primarily relate to the Company's receivables and liabilities in foreign currencies. The Swedish krona has weakened against the USD, EUR and GBP in the quarter, with the greatest effect in relation to the USD.

Operating result
The reported operating result amounted to SEK 89.6 million (54.9), including effects from the Group's long-term incentive programs. The adjusted operating result amounted to SEK 104.1 million (62.4).

Net financial items
The financial items amounted to a net income of SEK 7.5 million, to compare with a net expense of SEK 3.7 million in the corresponding quarter previous year. Included in the quarter were +SEK 6.8 million (-2.8) regarding the revaluation of swaps.

Income tax
During the quarter, the tax expense amounted to SEK 15.2 million, to compare with an income of SEK 1.9 million in the corresponding quarter previous year. For more information about the tax, see Note 6.

Result for the quarter
For the reasons described above, the result for the quarter amounted to SEK 81.9 million (53.1). This corresponds to earnings per share before dilution of SEK 1.24 (0.81) and after dilution of SEK 1.23 (0.79).

JANUARY – JUNE

Net sales
Net sales amounted to SEK 679.7 million (568.0), corresponding to an increase of 20 percent (31 percent at constant exchange rates). In the US segment, net sales amounted to SEK 562.3 million (466.8), which corresponds to growth of 20 percent (33 percent at constant exchange rate). Net sales for the EUROW segment amounted to SEK 117.4 million (101.1), which corresponds to a growth of 16 percent (21 percent at constant exchange rates).

Operating result
The reported operating result amounted to SEK 161.7 million (84.5). The adjusted operating result amounted to SEK 189.0 million (102.1).

Net financial items
The financial items amounted to an income of SEK 3.4 million, to compare with an expense of SEK 20.3 million previous year.

Income tax
Income tax amounted to SEK 29.9 million (0.7). For more information about the tax, see Note 6.

Result for the period
For the reasons described above, the result for the period amounted to SEK 135.3 million (63.5). This corresponds to earnings per share before dilution of SEK 2.05 (0.96) and after dilution of SEK 2.03 (0.95).

FINANCIAL POSITION AND CASH FLOWS

At the end of the period, cash and cash equivalents amounted to SEK 434.3 million, corresponding to an increase of SEK 56.3 million since the beginning of the year. The change is mainly explained by cash flows from operating activities amounting to SEK 142.0 million, reduced by the outgoing payment of SEK 82.9 million for repurchased ordinary shares. Furing the period, the Company executed a planned share buy-back program where 373,320 ordinary shares were repurchased for SEK 82.9 million including commissions.

Net cash increased with SEK 57.9 million since the beginning of the year.

Equity amounted to SEK 949.7 million at the end of the period, corresponding to an increase of SEK 82.4 million since the beginning of the year. This can mainly be explained by the result for the period.

FINANCIAL POSITION

	Jun 30		Dec 31
SEKm	2026	2025	2025
Cash and cash equivalents	434.3	309.7	378.0
Interest bearing debt[1]	10.1	12.7	11.7
Net cash[1]	**424.2**	**297.0**	**366.3**
Equity	**949.7**	**796.7**	**867.3**

1 For definitions and calculations of Alternative Performance Measures, see Pages 26-27.

CASH FLOWS

	Apr - Jun		Jan - Jun		Full year
SEKm	2026	2025	2026	2025	2025
Operating activities	67.1	49.8	142.0	96.5	221.3
Investing activities	-2.4	-2.2	-2.8	-3.0	-5.9
Financing activities	-86.5	-1.9	-86.7	-4.0	-58.0
Total	**-21.8**	**45.7**	**52.5**	**89.5**	**157.4**

PARENT COMPANY

The Parent Company, BONESUPPORT HOLDING AB (publ), is a holding company.

The Parent Company generated SEK 24.9 million (20.1) in sales of internal services to subsidiaries during the quarter. The corresponding year to date amount was SEK 49.7 million (40.2).

During the quarter, the financial net amounted to an expense of SEK 1.7 million, to compare with a positive net of SEK 2.3 million during the comparison quarter. The corresponding year to date amount was +SEK 2.6 million (+4.6).

The result for the quarter was -SEK 6.9 million (-1.7). The corresponding year to date amount was -SEK 11.6 million (+1.1).

No investments have been made during the year.

At the end of the period, cash in the Parent Company amounted to SEK 318.6 million, corresponding to an increase of SEK 74.2 million since the beginning of the year.

Equity in the Parent Company amounted to SEK 1,150.2 million at the end of the period, corresponding to a decrease of SEK 94.5 million since the beginning of the year.

For more information about the Parent Company, see the condensed financial statements on Pages 18-19.

OTHER DISCLOSURES

EMPLOYEES

On average, the Group had 171 (140) employees (full-time equivalents) during the quarter, of whom 39 (33) worked within Research and development.

SIGNIFICANT EVENTS DURING THE QUARTER

For significant events, see Page 2.

SIGNIFICANT EVENTS AFTER THE QUARTER

For significant events after the quarter, see Page 2.

FINANCIAL CALENDAR

- October 22, 2026 Interim report Q3

SHARES AND RELATED PROGRAMS

The Parent Company has ordinary shares and C-shares. The quotient value of the shares is SEK 0.625 per share. The ordinary shares entitle to one vote each and the C-shares entitle to one tenth of a vote each. According to the Articles of Association, the number of shares shall be at least 29,000,000 and at most 116,000,000.

At June 30, 2026, the total number of ordinary shares amounted to 65,859,195, distributed among 19,418 shareholders. The major shareholders are shown in the table on this page. BONESUPPORT HOLDING AB holds 373,320 of these shares. There have been no changes to the number of ordinary shares during the quarter.

At June 30, 2026, the total number of C-shares amounted to 905,155. BONESUPPORT HOLDING AB holds all C-shares. There have been no changes to the number of C-shares during the quarter.

For more information about the shares, see Note 8.

BONESUPPORT has three performance share programs. These are described in Note 5.

NOMINATION COMMITTEE

The nomination committee is elected based on the principles decided at the AGM on May 17, 2023. These principles are described on BONESUPPORT's website. The task of the committee is to present a proposal to the AGM, which is planned to be held in May 2027 in Lund, Sweden. The members of the committee are:

- Caroline Sjösten, appointed by Swedbank Robur Funds
- Erik Selin, appointed by Erik Selin Fastigheter
- Anna Sundberg, appointed by Handelsbanken Funds

In addition, the chair of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the nomination committee except when the nomination committee shall address the matter of chair of the Board and remuneration to the chair of the Board. The nomination committee will appoint one of its members as committee chair.

ABOUT THIS REPORT

This report has been prepared in both a Swedish-language and an English-language version. If the versions do not conform, the Swedish-language version shall prevail.

SHAREHOLDERS AT JUNE 30, 2026

Name	% of shares	% of votes
Swedbank Robur Fonder	9.73%	9.85%
Erik Selin	7.58%	7.67%
Capital Group	5.13%	5.19%
Handelsbanken Funds	4.37%	4.42%
SEB Funds	4.04%	4.09%
Avanza Pension	3.50%	3.54%
Vanguard	3.45%	3.49%
Other shareholders	62.20%	61.75%

Source: Monitor from Modular Finance AB. Compiled and aggregated data at June 30, 2026 from Euroclear, Morningstar and the SFSA.

DECLARATION OF THE BOARD OF DIRECTORS AND THE CEO

The Board of Directors and CEO assures that this interim report gives a true and fair view of the development and the Group's and the Parent Company's operations, position and results and describes significant risks and uncertainties faced by the companies that form part of the Group. This interim report has not been reviewed by the Company's auditors.

Lund July 16, 2026

Lennart Johansson
Chair of the Board

Emil Billbäck
Board member

Mary I O'Connor
Board member

Björn Odlander
Board member

Christine Rankin
Board member

Jens Viebke
Board member

Torbjörn Sköld
CEO

CONDENSED CONSOLIDATED INCOME STATEMENT

		Apr - Jun		Jan - Jun		Full year
SEKt	Note	2026	2025	2026	2025	2025
Net sales	3	355,724	284,425	679,747	567,969	1,174,661
Cost of sales	3	-32,702	-21,819	-57,814	-42,826	-87,333
Gross profit	3	**323,022**	**262,606**	**621,933**	**525,143**	**1,087,328**
Selling expenses		-83,406	-67,218	-167,944	-140,199	-286,294
Sales commissions and fees	3	-95,334	-79,432	-181,033	-158,763	-329,490
Research and development expenses		-24,812	-23,583	-49,863	-47,393	-91,397
Administrative expenses	4, 5	-34,397	-26,097	-65,158	-52,719	-103,477
Total operating expenses		**-237,949**	**-196,330**	**-463,998**	**-399,074**	**-810,658**
Other operating income		8,149	19,500	11,718	34,067	66,364
Other operating expenses		-3,665	-30,902	-7,940	-75,614	-111,359
Operating result	3	**89,557**	**54,874**	**161,713**	**84,522**	**231,675**
Net financial items	3	7,541	-3,737	3,407	-20,296	-32,157
Result before income tax	3	**97,098**	**51,137**	**165,120**	**64,226**	**199,518**
Income tax	6	-15,221	1,933	-29,863	-729	-57,364
Result for the period		**81,877**	**53,070**	**135,257**	**63,497**	**142,154**
Earnings per share before dilution, SEK	8	1.24	0.81	2.05	0.97	2.16
Earnings per share after dilution, SEK	8	1.23	0.79	2.03	0.95	2.13
Average number of shares, thousands		65,859	65,859	65,859	65,632	65,859
Average number of shares after dilution, thousands		66,774	66,759	66,777	66,608	66,778

Result for the period is attributable to equity holders of the Parent Company.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Apr - Jun		Jan - Jun		Full year
SEKt	2026	2025	2026	2025	2025
Result for the period	**81,877**	**53,070**	**135,257**	**63,497**	**142,154**
Other comprehensive income:					
Items to be reclassified to profit or loss in subsequent periods:					
Exchange differences on translation of foreign operations	2,272	-2,923	11,117	-10,336	-18,370
Total comprehensive income for the period	**84,149**	**50,147**	**146,374**	**53,161**	**123,784**

Total comprehensive income for the period is in its entirety attributable to equity holders of the Parent Company.

CONDENSED CONSOLIDATED BALANCE SHEET

		Jun 30		Dec 31
SEKt	Note	2026	2025	2025
ASSETS				
Non-current assets				
Intangible assets		15,383	14,752	14,914
Tangible assets and right of use assets	6	18,922	19,584	20,340
Deferred tax asset	6	176,285	233,737	203,112
Financial assets	7	775	743	1,111
Total non-current assets		**211,365**	**268,816**	**239,477**
Current assets				
Inventories		167,560	132,344	144,996
Trade receivables	7	221,714	190,402	215,552
Other current assets	7	84,428	61,586	58,126
Cash and cash equivalents	7	434,307	309,676	377,988
Total current assets		**908,009**	**694,008**	**796,662**
TOTAL ASSETS		**1,119,374**	**962,824**	**1,036,139**
EQUITY AND LIABILITIES				
Equity attributable to equity holders of the Parent	6, 8	**949,657**	**796,716**	**867,260**
Non-current liabilities				
Leasing debt	6, 7	2,467	5,668	4,200
Provisions		332	377	358
Total non-current liabilities		**2,799**	**6,045**	**4,558**
Current liabilities				
Leasing debt	6, 7	7,664	7,010	7,483
Trade payables	7	28,869	18,995	16,441
Other operating liabilities	7	130,385	134,058	140,397
Total current liabilities		**166,918**	**160,063**	**164,321**
TOTAL EQUITY AND LIABILITIES		**1,119,374**	**962,824**	**1,036,139**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Share capital	Other paid in capital	Translation reserve	Balanced result including result for the period	Total equity
SEKt					
As at January 1, 2025	**41,728**	**1,565,929**	**6,578**	**-886,770**	**727,464**
Comprehensive income					
Result January - June 2025			-10,336	63,497	53,161
Total comprehensive income			**-10,336**	**63,497**	**53,161**
Transactions with equity holders					
Transaction costs, share issue				-58	-58
Deferred tax on transaction costs				12	12
Share-based payment transactions				16,137	16,137
Total transactions with equity holders	**0**	**0**	**0**	**16,091**	**16,091**
As at June 30, 2025	**41,728**	**1,565,929**	**-3,758**	**-807,182**	**796,716**
Comprehensive income					
Result July - December 2025			-8,034	78,657	70,623
Total comprehensive income			**-8,034**	**78,657**	**70,623**
Transactions with equity holders					
Share swap, own shares				-16,250	-16,250
Share-based payment transactions				16,171	16,171
Total transactions with equity holders	**0**	**0**	**0**	**-79**	**-79**
As at January 1, 2026	**41,728**	**1,565,929**	**-11,792**	**-728,604**	**867,260**
Comprehensive income					
Result January - June 2026			11,117	135,257	146,374
Total comprehensive income			**11,117**	**135,257**	**146,374**
Transactions with equity holders					
Buy-back of ordinary shares				-82,875	-82,875
Transaction costs				-83	-83
Deferred tax on transaction costs				17	17
Share-based payment transactions				18,964	18,964
Total transactions with equity holders	**0**	**0**	**0**	**-63,977**	**-63,977**
As at June 30, 2026	**41,728**	**1,565,929**	**-675**	**-657,324**	**949,657**

CONSOLIDATED STATEMENT OF CASH FLOWS

	Apr - Jun		Jan - Jun		Full year
SEKt	2026	2025	2026	2025	2025
Operating result	89,557	54,874	161,713	84,522	231,675
Non-cash adjustments:					
-Share-based payments	9,558	5,732	18,964	16,137	32,308
-Depreciation regarding right of use assets	2,141	1,841	4,292	3,679	7,736
-Unrealized exchange rate differences	-2,996	-3,563	-359	35,991	36,839
-Other	2,922	923	5,326	2,005	6,881
Interests received	271	30	428	71	7,471
Interests paid	1,149	-967	-452	-2,678	-468
Income tax paid	-17,803	-6,739	-21,989	-10,485	-32,134
Net cash flows from operating activities before changes in working capital	**84,799**	**52,131**	**167,923**	**129,242**	**290,308**
Changes in working capital	-17,712	-2,298	-25,907	-32,781	-69,004
Net cash flows from operating activities	**67,087**	**49,833**	**142,016**	**96,461**	**221,304**
Investments in intangible assets	-1,247	-733	-1,671	-1,309	-2,633
Investments in equipment and tools	-1,241	-1,235	-1,471	-1,398	-2,562
Returned deposit (+) / investments in financial assets (-)	120	-197	336	-317	-685
Net cash flows from investing activities	**-2,368**	**-2,165**	**-2,806**	**-3,024**	**-5,880**
Share swap, own shares	0	0	0	0	-16,250
Share swap, derivative	0	0	0	0	-33,168
Repurchase of ordinary shares	-82,875	0	-82,875	0	0
Transaction costs, share issue	-83	0	-83	-58	-58
Repayments of leasing debt	-3,549	-1,929	-3,704	-3,904	-8,561
Net cash flows from financing activities	**-86,507**	**-1,929**	**-86,662**	**-3,962**	**-58,037**
Net cash flows	**-21,788**	**45,739**	**52,548**	**89,475**	**157,387**
Cash and cash equivalents as at beginning of period	455,260	227,004	377,988	227,004	227,004
Net foreign exchange difference	835	-3,198	3,771	-6,803	-6,403
Cash and cash equivalents as at end of period	**434,307**	**269,545**	**434,307**	**309,676**	**377,988**

CONDENSED CONSOLIDATED INCOME STATEMENT PER QUARTER

	2026		2025				2024	
SEKt	**Q2**	**Q1**	**Q4**	**Q3**	**Q2**	**Q1**	**Q4**	**Q3**
Net sales	355,724	324,023	312,549	294,143	284,425	283,544	257,010	237,503
US	295,183	267,118	258,769	246,303	235,617	231,220	209,417	192,039
EUROW	60,541	56,905	53,780	47,840	48,808	52,324	47,593	45,464
Cost of sales	-32,702	-25,112	-23,578	-20,929	-21,819	-21,007	-18,980	-16,874
Gross profit	**323,022**	**298,911**	**288,971**	**273,214**	**262,606**	**262,537**	**238,030**	**220,629**
Gross margin, %	**90.8%**	**92.2%**	**92.5%**	**92.9%**	**92.3%**	**92.6%**	**92.6%**	**92.9%**
Selling expenses	-83,406	-84,538	-79,823	-66,272	-67,218	-72,981	-71,237	-65,478
Sales commissions and fees	-95,334	-85,699	-85,647	-85,080	-79,432	-79,331	-70,409	-65,506
Research and development expenses	-24,812	-25,051	-23,454	-20,550	-23,583	-23,810	-21,838	-19,684
Administrative expenses	-34,397	-30,761	-20,496	-30,262	-26,097	-26,622	-30,096	-22,754
Total operating expenses	**-237,949**	**-226,049**	**-209,420**	**-202,164**	**-196,330**	**-202,744**	**-193,580**	**-173,422**
Other operating income	8,149	3,569	18,703	13,594	19,500	14,567	44,022	14,234
Other operating expenses	-3,665	-4,275	-16,490	-19,255	-30,902	-44,712	-24,257	-20,478
Operating result	**89,557**	**72,156**	**81,764**	**65,389**	**54,874**	**29,648**	**64,215**	**40,963**
Net financial items	7,541	-4,134	-13,242	1,381	-3,737	-16,559	7,854	-349
Result before income tax	**97,098**	**68,022**	**68,522**	**66,770**	**51,137**	**13,089**	**72,069**	**40,614**
Income tax	-15,221	-14,642	-24,373	-32,262	1,933	-2,662	-18,156	-10,045
Result for the period	**81,877**	**53,380**	**44,149**	**34,508**	**53,070**	**10,427**	**53,913**	**30,569**

Result for the period is attributable to equity holders of the Parent Company.

CONDENSED PARENT COMPANY INCOME STATEMENT

		Apr - Jun		Jan - Jun		Full year
SEKt	**Note**	**2026**	**2025**	**2026**	**2025**	**2025**
Net sales		24,869	20,122	49,738	40,245	81,683
Administrative expenses	5	-30,439	-23,438	-59,366	-46,094	-94,310
Other operating income		0	-995	0	2,689	5,218
Other operating expenses		-1,431	-60	-2,372	-60	-137
Operating result		**-7,001**	**-4,371**	**-12,000**	**-3,220**	**-7,546**
Net financial items		-1,698	2,310	-2,554	4,565	-21,719
Result after financial items		**-8,699**	**-2,061**	**-14,554**	**1,345**	**-29,265**
Income tax	6	1,815	323	2,989	-277	2,646
Result for the period		**-6,884**	**-1,738**	**-11,565**	**1,068**	**-26,619**

Parent Company result for the period equals comprehensive income.

CONDENSED PARENT COMPANY BALANCE SHEET

		Jun 30		Dec 31
SEKt	Note	2026	2025	2025
ASSETS				
Non-current assets				
Deferred tax asset	6	37,770	31,518	34,764
Non-current financial assets	7	956,652	1,333,620	1,041,058
Total non-current assets		**994,422**	**1,365,138**	**1,075,822**
Current assets				
Other receivables	7	0	0	150
Prepaid expenses		5,606	5,341	2,515
Cash	7	318,558	761	244,350
Total current assets		**324,164**	**6,102**	**247,015**
TOTAL ASSETS		**1,318,586**	**1,371,240**	**1,322,837**
EQUITY AND LIABILITIES				
Equity				
Restricted equity	5	41,728	41,728	41,728
Unrestricted equity	6	1,108,455	1,247,388	1,202,961
Total equity		**1,150,183**	**1,289,116**	**1,244,689**
Non-current liabilities		**146,062**	**63,797**	**64,106**
Current liabilities	7	**22,341**	**18,327**	**14,042**
TOTAL EQUITY AND LIABILITIES		**1,318,586**	**1,371,240**	**1,322,837**

NOTE 1 – GENERAL INFORMATION, ACCOUNTING PRINCIPLES

This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The Parent Company's reporting has been prepared in accordance with RFR 2 Reporting for Legal Entities and the Swedish Annual Accounts Act. The accounting principles mentioned in the Annual Report for 2025 have also been applied in this interim report.

BONESUPPORT has elected not to early apply new standards, amendments and interpretations that have been published but are not effective until the financial year beginning after January 1, 2027 or later. The standard expected to affect BONESUPPORT is IFRS 18 Presentation and Disclosures in Financial Statements which is applicable for financial years beginning on or after January 1, 2027. IFRS 18 will not affect the recognition or measurement of items in BONESUPPORT's financial statements, but is expected to have effects on presentation and disclosures, particularly those related to the income statement and performance measures defined by BONESUPPORT. BONESUPPORT is currently evaluating the consequences of applying the new standard to the consolidated financial statements.

In the Group, there are performance share programs. To secure the delivery of performance shares in two of these, share swap agreements have been entered into. The first of these swaps relates to the program LTI 2024/2027 and was signed in 2024 in accordance with a resolution from the 2024 Annual General Meeting. Based on the terms of that agreement, BONESUPPORT has assessed that the instrument should be classified as a derivative and be measured at fair value. The second of the swaps relates to LTI 2025/2028 and was signed in 2025 in accordance with a resolution from the 2025 Annual General Meeting. Based on the terms of that agreement, BONESUPPORT has assessed that the instrument constitutes an equity instrument. The main difference in the assessment of how the share swaps should be handled is that the latter share swap has an advance payment and therefore does not meet the definition of a derivative, while the one made in 2024 does not have such an advance payment and is thus considered to be a derivative.

Estimates, assumptions and assessments

When preparing the Group's financial reports, the Group management team makes estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses with associated notes and information on contingent liabilities. Uncertainty around these assumptions and estimates can lead to significant adjustments to the reported values of the affected assets and liabilities in future financial reports as the outcome may deviate from the estimates and assessments made. Changes in estimates are reported prospectively. The Group management team also makes assessments in the application of the Group's accounting principles.

The assessment that has the most significant effect on the reported values in the financial reports concerns the determination of the Company's marginal borrowing rate which is used to calculate the Company's leasing debt. As the Company does not have external loan financing, the information on marginal loan interest is based on information received from the Group's main bank.

Key assumptions regarding the future and sources of uncertainty in estimates made on the balance sheet date, that have a significant risk of resulting in a material adjustment of assets and liabilities in the coming quarters, regard three main areas of valuation: tax losses carried forward, trade receivables and shares in Group companies.

NOTE 2 – SIGNIFICANT RISKS AND UNCERTAINTIES

Through its operations, the Group is exposed to various types of financial risks, such as market, liquidity and credit risk. BONESUPPORT runs its business and its operations on the international market and is therefore exposed to currency risks as its revenues and expenses arise in different currencies, of which mainly EUR, GBP and USD. The operational activities include continuously identifying and managing risks. Financial risk management is described in Note 2 of the Annual Report for 2025.

The current global situation with geopolitical uncertainty, war and potential international tariffs is closely monitored by management and any impact is continuously evaluated, including necessary measures to take to limit any impact on BONESUPPORT. When importing goods to the US, the Company pays a general tariff of 10 percent, which over time will reduce the gross margin of the US segment with approximately 0.8 percentage points.

NOTE 3 – OPERATING SEGMENTS AND REVENUE FROM CONTRACTS WITH CUSTOMERS

The Group's revenues from contracts with customers is displayed in the table above as Net sales. The revenues are divided by product group; CERAMENT BVF, CERAMENT G and CERAMENT V, and other.

The Group manages and monitors operations in the US and Europe & Rest of the World (EUROW) segments. The segment named Other comprises other non-allocated items, of which mainly costs for Group functions.

The CEO of BONESUPPORT together with the other members of the Group Management Team are the Group's Chief Operating Decision Maker. Together, they manage and monitor operations in the two main operating segments: US and EUROW. The sales function follows the segments, where each segment is managed by a responsible business manager, who is also part of the Group management team. Other functions are mainly organized Group-wide, with exception of a small team within Research and development operating in the United States. The costs included in Other are mainly those for Group functions that cannot be directly allocated to any of the two main operating segments. The contribution per operating segment is calculated as the segment's net sales minus the operative items that are directly attributable to the segment. Assets and liabilities are not reported by segment, as these are managed and monitored on Group level by management and the Board of Directors.

The only market that delivered more than 10 percent of net sales during the quarter was the United States with SEK 295.2 million (234.5). Net sales in Sweden (part of EUROW) amounted to SEK 3.3 million (2.8). Year to date, net sales amounted to SEK 562.3 million (465.7) for the US and SEK 7.1 milion (6.4) for Sweden. No customer represented more than 10 percent of net sales during the period or its comparison period.

SEKt	Apr - Jun 2026				Apr - Jun 2025			
Profit and loss items	**US**	**EUROW**	**Other**	**Total**	**US**	**EUROW**	**Other**	**Total**
Net sales	295,183	60,541	0	355,724	235,617	48,808	0	284,425
of which CERAMENT BVF	*42,194*	*6,364*	*0*	*48,558*	*49,123*	*4,664*	*0*	*53,787*
of which CERAMENT drug eluting	*243,505*	*53,972*	*0*	*297,478*	*179,806*	*44,025*	*0*	*223,831*
of which other	*9,484*	*204*	*0*	*9,688*	*6,689*	*122*	*0*	*6,811*
Cost of sales	-18,281	-11,749	-2,672	-32,702	-12,491	-8,522	-806	-21,819
Gross profit	**276,902**	**48,792**	**-2,672**	**323,022**	**223,126**	**40,286**	**-806**	**262,606**
Sales commissions and fees	-94,691	-643	0	-95,334	-78,535	-897	0	-79,432
Other operative items	-42,054	-31,379	0	-73,433	-40,144	-25,798	0	-65,942
Contribution	**140,157**	**16,770**	**-2,672**	**154,255**	**104,447**	**13,591**	**-806**	**117,232**
Other operating items	0	0	-64,698	-64,698	0	0	-62,358	-62,358
Operating result	**140,157**	**16,770**	**-67,370**	**89,557**	**104,447**	**13,591**	**-63,164**	**54,874**
Net financial items	0	0	7,541	7,541	0	0	-3,737	-3,737
Result before income tax	**140,157**	**16,770**	**-59,829**	**97,098**	**104,447**	**13,591**	**-66,901**	**51,137**

SEKt	Jan - Jun 2026				Jan - Jun 2025			
Profit and loss items	**US**	**EUROW**	**Other**	**Total**	**US**	**EUROW**	**Other**	**Total**
Net sales	562,301	117,446	0	679,747	466,837	101,132	0	567,969
of which CERAMENT BVF	*79,284*	*12,102*	*0*	*91,386*	*95,471*	*9,548*	*0*	*105,019*
of which CERAMENT drug eluting	*465,612*	*104,976*	*0*	*570,587*	*357,775*	*91,334*	*0*	*449,109*
of which other	*17,405*	*368*	*0*	*17,774*	*13,591*	*250*	*0*	*13,841*
Cost of sales	-33,058	-22,031	-2,725	-57,814	-24,053	-17,536	-1,237	-42,826
Gross profit	**529,243**	**95,415**	**-2,725**	**621,933**	**442,784**	**83,596**	**-1,237**	**525,143**
Sales commissions and fees	-179,800	-1,233	0	-181,033	-157,302	-1,461	0	-158,763
Other operative items	-86,613	-64,698	0	-151,311	-83,903	-53,176	0	-137,079
Contribution	**262,830**	**29,484**	**-2,725**	**289,589**	**201,579**	**28,959**	**-1,237**	**229,301**
Other operating items	0	0	-127,876	-127,876	0	0	-144,779	-144,779
Operating result	**262,830**	**29,484**	**-130,601**	**161,713**	**201,579**	**28,959**	**-146,016**	**84,522**
Net financial items	0	0	3,407	3,407	0	0	-20,296	-20,296
Result before income tax	**262,830**	**29,484**	**-127,194**	**165,120**	**201,579**	**28,959**	**-166,312**	**64,226**

The amounts in the table above are eliminated for Group transactions. Intercompany sales from EUROW to the US segment amounted to SEK 17.0 million (11.6) during the quarter and SEK 25.2 million (31.5) year to date.

CERAMENT drug eluting includes CERAMENT G and CERAMENT V.

NOTE 4 – TRANSACTIONS WITH RELATED PARTIES

The financial reports include costs related to the following transactions between BONESUPPORT and related parties.

SEKt		Apr - Jun		Jan - Jun		Full year
Related party	**Service/nature of invoice**	**2026**	**2025**	**2026**	**2025**	**2025**
Lennart Johansson (Chair)	Reimbursement of expenses	13	0	27	4	7
Emil Billbäck (Board member)	Reimbursement of expenses	0	0	0	0	0
Mary I O'Connor (Board member)	Consultancy	247	256	488	538	1,037
Mary I O'Connor (Board member)	Reimbursement of expenses	1	0	61	0	54
Björn Odlander (Board member)	Reimbursement of expenses	0	0	1	0	1
Christine Rankin (Board member)	Reimbursement of expenses	2	0	7	8	12
Jens Viebke (Board member)	Reimbursement of expenses	1	0	7	0	12

The expenses for Emil Billbäck regard the time since he became Board member, on May 12, 2026.

NOTE 5 – PERFORMANCE SHARE PROGRAMS

At the end of the period, there were three performance share programs, so called Long Term Incentive programs ("LTI").

LTI 2023 that was decided at the Annual General Meeting in 2023 runs until December 31, 2026. The investment period for the participants ended on December 31, 2023 and the vesting period started on January 1, 2024. In the program, each savings share gives the opportunity to be allotted a maximum of four performance shares without payment depending on share price development and the Company's development in terms of sales and EBITDA during the duration of the program.

LTI 2024 that was decided at the Annual General Meeting in 2024 runs until December 31, 2027. The investment period for the participants ended on September 30, 2024 and the vesting period started on the same day. In the program, each savings share gives the opportunity to be allotted a maximum of three performance shares without payment depending on share price development and the Company's development in terms of sales and EBITDA during the duration of the program.

LTI 2025 that was decided at the Annual General Meeting in 2025 runs until December 31, 2028. The investment period for the participants ended on September 30, 2025 and the vesting period started on January 1, 2026. In the program, each savings share gives the opportunity to be allotted a maximum of three performance shares without payment depending on share price development and the Company's development in terms of sales and EBITDA during the duration of the program.

Change in number of potential performance shares during the period	Right to no. of shares
January 1, 2026	914,750
June 30, 2026	**914,750**

Performance shares are valued at fair value at the date of allocation. The total cost for them is distributed over the vesting period. Towards the end of the vesting period, a reduction in staff turnover is assumed, which entails an increased cost. The cost is recognized as a personnel cost among the administrative expenses, and is credited to equity - see the consolidated statement of changes in equity, on Page 16. The social security cost is valued at fair value.

The year to date cost for performance share programs, excluding social security contributions, affected the operating result with SEK 18,964 thousand (16,137). Social security contributions for these programs amounted to an expense of SEK 8,292 thousand (1,464). The liability for social security contributions at the end of the period amounted to SEK 23,344 thousand (18,476).

Further information on these programs is presented in Notes 12 and 23 of the Annual Report for 2025.

NOTE 6 – INCOME TAX

The Group has tax losses carried forward based on historical losses. The losses carried forward are attributable to the research-focused period of the business, where the foundation and conditions for current and future sales and results were created. The tax losses carried forward amounted to SEK 951 million (690) at the beginning of the year. They essentially apply towards the same tax authority, which together with full group contribution rights within the Swedish part of the Group means that all deficits can be recovered.

The valuation of tax losses in Sweden and when they are expected to be utilized is evaluated on an ongoing basis.

In the Group and in the Parent Company, deferred tax that relates to transaction costs on share issue and similar transactions, is recognized directly over equity, as that is where the transaction costs are recognized. The remaining part of the deferred tax is expensed.

GROUP	Apr - Jun		Jan - Jun		Full year
SEKt	2026	2025	2026	2025	2025
Deferred tax expense (-) / benefit (+)	-15,824	14,308	-27,012	12,502	-18,052
Current tax expense (-) / benefit (+)	603	-12,375	-2,851	-13,231	-39,312
Total income tax	**-15,221**	**1,933**	**-29,863**	**-729**	**-57,364**

	Jun 30		Dec 31
SEKt	2026	2025	2025
Deferred tax asset on tax losses, recognized in the income statement	157,283	170,154	183,223
Deferred tax asset on tax losses, recognized directly over equity	12,604	12,012	12,587
Deferred tax asset on leasing debt	2,510	3,021	2,825
Deferred tax liability on right of use assets	-2,539	-2,890	-2,977
Deferred tax asset on other temporary differences	6,427	51,440	7,454
Total deferred tax asset (net)	**176,285**	**233,737**	**203,112**

PARENT COMPANY	Apr - Jun		Jan - Jun		Full year
SEKt	2026	2025	2026	2025	2025
Deferred tax expense (-) / benefit (+)	1,815	678	2,989	-24	2,646
Current tax expense (-) / benefit (+)	0	-355	0	-253	0
Total income tax	**1,815**	**323**	**2,989**	**-277**	**2,646**

	Jun 30		Dec 31
SEKt	2026	2025	2025
Deferred tax asset on tax losses, recognized in the income statement	25,166	19,506	22,177
Deferred tax asset on tax losses, recognized directly over equity	12,604	12,012	12,587
Total deferred tax asset	**37,770**	**31,518**	**34,764**

NOTE 7 – FINANCIAL ASSETS AND LIABILITIES

Fair values of the consolidated financial assets and liabilities are assessed to agree with values accounted for.

Participations in subsidiaries are recognized in the Parent Company in accordance with the cost method.

NOTE 8 – SHARE CAPITAL AND NUMBER OF SHARES INCLUDING POTENTIAL SHARES

Ordinary shares	Number of shares	Number of potential shares	Total
January 1, 2026	65,859,195	914,750	66,773,945
June 30, 2026	**65,859,195**	**914,750**	**66,773,945**
Series C-shares			
January 1, 2026	905,155	0	905,155
June 30, 2026	**905,155**	**0**	**905,155**
Total	**66,764,350**	**914,750**	**67,679,100**

The total number of shares at the end of the period was 66,764,350 (66,764,350) of which 65,859,195 (65,859,195) were ordinary shares and 905,155 (905,155) were series C-shares. The share capital in the Group and the Parent Company consists of the total number of shares valued at the quotient value of SEK 0.625 per share.

Potential shares regards 584,000 shares in performance share program LTI 2023, 261,000 shares in LTI 2024 and 69,750 shares in LTI 2025. For more information, see Note 5.

Earnings per share - before dilution

Earnings per share before dilution is calculated using the following results and number of shares:

	Apr - Jun		Jan - Jun		Full year
	2026	**2025**	**2026**	**2025**	**2025**
Result for the period, SEK thousands	81,877	53,070	135,257	63,497	142,154
Weighted average number of ordinary shares, thousands	65,859	65,859	65,859	65,632	65,859
Earnings per share before dilution, SEK	**1.24**	**0.81**	**2.05**	**0.97**	**2.16**

Earnings per share - after dilution

BONESUPPORT has potential shares in form of current long term incentive programs. Earnings per share after dilution is calculated as follows:

	Apr - Jun		Jan - Jun		Full year
	2026	**2025**	**2026**	**2025**	**2025**
Result for the period, SEK thousands	81,877	53,070	135,257	63,497	142,154
Weighted average number of ordinary and potential shares, thousands	66,774	66,759	66,777	66,608	66,777
Earnings per share after dilution, SEK	**1.23**	**0.79**	**2.03**	**0.95**	**2.13**

NOTE 9 – PLEDGED SECURITIES AND CONTINGENT LIABILITIES

The US subsidiary BONESUPPORT Inc. has provided a guarantee of USD 42 thousand (42), corresponding to SEK 409 thousand (399), for rented premises. The ultimate Parent Company, BONESUPPORT HOLDING AB, guarantees a corresponding amount. The Parent Company has also provided a general guarantee, which at the end of the year amounted to USD 1,000 thousand (1,000), corresponding to SEK 9,736 thousand (9,490.

The Group has pledged collateral for capital-invested direct pensions amounting to SEK 979 thousand (979).

ALTERNATIVE PERFORMANCE MEASURES AND FINANCIAL DEFINITIONS

	Apr - Jun		Jan - Jun		Full year
SEKm	2026	2025	2026	2025	2025
Net sales	355.7	284.4	679.7	568.0	1,174.7
Cost of sales	-32.7	-21.8	-57.8	-42.8	-87.3
Gross profit	**323.0**	**262.6**	**621.9**	**525.1**	**1,087.3**
Gross margin, %	**90.8**	**92.3**	**91.5**	**92.5**	**92.6**
Directly attributable selling expenses	-167.4	-144.5	-329.7	-294.1	-602.2
Selling expenses, not directly attributable	-11.4	-2.2	-19.3	-4.9	-13.6
Selling expenses including commissions and fees	-178.7	-146.7	-349.0	-299.0	-615.8
Directly attributable research and development expenses	-1.3	-0.9	-2.5	-1.8	-5.5
Research and development expenses, not directly attributable	-23.5	-22.7	-47.3	-45.6	-85.9
Research and development expenses	-24.8	-23.6	-49.9	-47.4	-91.4
Directly attributable other operating income and expenses	0.0	0.0	0.0	0.0	4.9
Other operating income and expenses, not directly attributable	4.5	-11.4	3.8	-41.5	-49.9
Other operating income and expenses	4.5	-11.4	3.8	-41.5	-45.0
Contribution	**154.3**	**117.2**	**289.6**	**229.3**	**484.5**

Net sales growth
The difference in net sales between two periods in relation to the net sales for the earlier period. Shows the operations' sales performance.

Net sales growth in constant exchange rates (CER)
The difference in net sales between two periods in relation to net sales for the earlier period. The net sales for the current period is recalculated using the earlier period's exchange rates. Shows the operations' sales performance.

	Apr - Jun			Jan - Jun		
SEKm	2026	2025	Net sales growth	2026	2025	Net sales growth
Segment US	295.2	235.6	25%	562.3	466.8	20%
Segment EUROW	60.5	48.8	24%	117.4	101.1	16%
Net sales	**355.7**	**284.4**	**25%**	**679.7**	**568.0**	**20%**

	Apr - Jun			Jan - Jun		
SEKm	2026 CER	2025	Net sales growth CER	2026 CER	2025	Net sales growth CER
Segment US	307.6	235.6	31%	619.3	466.8	33%
Segment EUROW	61.4	48.8	26%	122.0	101.1	21%
Net sales, for which 2026 is in CER	**369.0**	**284.4**	**30%**	**741.3**	**568.0**	**31%**

BONESUPPORT uses Alternative Performance Measures (APM) to enhance understandability of the information in its financial reports, both for external analysis and comparison and internal performance assessment.

Alternative Performance Measures are key figures not defined in financial reports prepared according to IFRS. The following key figures are used:

Gross profit
Net sales less cost of sales. Shows the profit to cover other expenses and profit margin.

Gross margin
Gross profit divided by net sales. Shows the gross profit in relation to net sales and the margin to cover other expenses and profit margin.

Contribution
Gross margin minus directly attributable income and expenses for selling, as well as research and development. A measure of result showing the performance of segments and their contribution to cover other Group costs.

ALTERNATIVE PERFORMANCE MEASURES AND FINANCIAL DEFINITIONS, cont'd

Adjusted operating result

Operating result before expenses for the technical accounting measures of IFRS 2 and also before with the change in the liability for social security contributions for these long term incentive programs.

	Apr - Jun		Jan - Jun		Full year
SEKm	2026	2025	2026	2025	2025
Operating result	89.6	54.9	161.7	84.5	231.7
Of which incentive costs	-14.5	-7.6	-27.3	-17.6	-30.4
Adjusted operating result	**104.1**	**62.4**	**189.0**	**102.1**	**262.0**

Interest bearing debt

Leasing debt, current and non-current. Shows the debt level of the Group and forms the base for interest expenses.

Net cash

Cash and cash equivalents minus interest bearing debt. This APM is used to measure future funding needs.

	Jun 30		Dec 31
SEKm	2026	2025	2025
Cash and cash equivalents	434.3	309.7	378.0
Current leasing debt	2.5	5.7	4.2
Non-current leasing debt	7.7	7.0	7.5
Interest bearing debt	10.1	12.7	11.7
Net cash	**424.2**	**297.0**	**366.3**

Operating margin

The operating result in relation to net sales for the same period.

	Apr - Jun		Jan - Jun		Full year
SEKm	2026	2025	2026	2025	2025
Net sales	355.7	284.4	679.7	568.0	1,174.7
Operating result	89.6	54.9	161.7	84.5	231.7
Operating margin, %	25%	19%	24%	15%	20%

RESEARCH AND DEVELOPMENT

BONESUPPORT's clinical development program focuses on developing the Company's platform technology, CERAMENT. The unique properties of CERAMENT create opportunities to continuously broaden and expand the clinical application areas and utilize CERAMENT's drug-eluting capabilities through the development of combination products that primarily promote bone healing and protect against infection. One of the three pillars of BONESUPPORT's strategy is to deliver industry-leading scientific and clinical evidence that validates the many benefits of CERAMENT. Today, there is already a comprehensive and growing database with more than 350 research publications and abstracts of preclinical and clinical studies involving CERAMENT. More than 2,000 patients have participated in clinical studies within current indication areas.

During 2026, the Company continues to invest in generating evidence and supporting third-party initiatives that can open up for new areas of use as well as strengthen and expand established segments for CERAMENT both in terms of healing of skeletal injuries and infection management. The focus is on medical conditions that involve great patient suffering, a high risk of complications and large costs for healthcare systems in the indication areas of Trauma, Foot & Ankle Injuries, Joint revisions and Spinal Surgery. At the Company's Capital Markets Day in May 2026, the Company also announced plans to invest in and initiate clinical studies in 2027. The studies will evaluate the use of antibiotic-eluting CERAMENT in revision arthroplasty and spine surgery, respectively, and are expected to further strengthen the clinical evidence base in these prioritized growth areas.

In addition, work is underway to make the entire CERAMENT platform available in existing markets and to register the products in markets with growth potential.

THE SOLARIO STUDY

The SOLARIO[1] study is a randomized open non-inferiority European multicenter study on 500 patients with orthopedic infection. The Company has supported the study through a clinical research grant to EBJIS (European Bone & Joint Infection Society). In September 2024, the overall results from the study were presented, showing that patients treated surgically with antibiotic-releasing bone substitutes such as CERAMENT G and CERAMENT V achieved equally good infection prevention with a short systemic antibiotic course of up to seven days, compared to the previous standard treatment, which in the study was at least four weeks. Given that most patients received two or more antibiotics in parallel, this resulted in a total of 11,275 fewer antibiotic days in the shorter treatment arm. The group that received the shorter antibiotic treatment showed significantly fewer and milder side effects than the group with the longer antibiotic treatment. The results are expected to lead to a paradigm shift in the surgical treatment of bone infection, including reduced treatment time and costs for antibiotics, fewer side effects, better patient compliance, improved antibiotic use, and reduced risk of antibiotic resistance.

CERAMENT IN TRAUMA

Preclinical research

Several combinations with CERAMENT have previously been investigated to add osteoinductive properties, i.e. the ability to actively stimulate bone healing. Among other things, the Company has conducted research where CERAMENT has been combined with bisphosphonates. Bisphosphonates are a well-established substance used in the treatment of osteoporosis to inhibit osteoclast activity, resulting in improved bone healing and bone density. Preclinical research has shown that the addition of zoledronic acid to CERAMENT increases bone volume around screw implants in osteoporotic bone and that CERAMENT significantly improves the anchoring of implant screws[2].

Further preclinical research has shown that the combination of CERAMENT, zoledronic acid and bone morphogenetic protein-2 (BMP-2) can also be used in the reconstruction of large segmental defects as an alternative to bone grafting.

Progress in the quarter

To strengthen the foundation for future growth and expand its long-term market potential, the Company announced at its Capital Markets Day in May plans to initiate clinical studies in 2027 within arthroplasty and spine surgery.

1 Dudareva M, Kumin M, Vach W, Kaier K, Ferguson J, McNally M, Scarborough M. "Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO): a randomized controlled open-label non-inferiority trial of duration of systemic antibiotics in adults with orthopaedic infection treated operatively with local antibiotic therapy". Trials 2019; 20: 693. Awaiting publication.
2 Deepak, Bushan, Raina et al. "A New Augmentation Method for Improved Screw Fixation in Fragile Bone". Frontiers in Bioengineering and Biotechnology, Volume 10 | Article 816250 | March 2022.

Clinical evidence

CERTiFy[3], a randomized controlled study conducted at 20 trauma centers in Germany on 135 patients with tibial plateau fractures, shows that CERAMENT BVF achieves bone healing comparable to autograft (transplanted bone). Additionally, treatment with CERAMENT BVF led to significantly lower patient-reported postoperative pain and significantly less blood loss compared to autograft. The study, published in The Journal of Bone and Joint Surgery in December 2019, serves as an important vector for driving changes in standard of care.

In 2022, very strong results were presented from a long-term study[4] of CERAMENT G. A hundred patients treated at Nuffield Orthopaedic Centre, Oxford University Hospitals, for bone infection were followed for an average of six years. At the end of the study, it was concluded that:

- 94 percent of the patients remained infection-free.
- Within the first year after surgery, the fracture rate amounted to three percent. No further fractures thereafter.

In 2023, additional long-term data with CERAMENT G in connection with severe open fractures[5] were presented. Eighty-one patients with severe open fractures and significant tissue damage, who underwent a one-stage procedure with CERAMENT G at Manchester University Hospital, were followed for an average of 55.8 months after surgery. At the end of the study, it was concluded that 96.3 percent of patients avoided deep infection, avoided amputation and achieved bone healing within twelve months.

The results from these two studies, over a long follow-up period, confirm that treatment protocols with CERAMENT G remain highly effective for several years.

In March 2026, the first US clinical case series describing a surgical technique and early outcomes associated with the use of CERAMENT and intramedullary nailing in patients with open fractures was published[6]. Nine patients with open fractures of the tibia, femur, or humerus were treated with CERAMENT G, delivered using the Flow-FX™ 2-CAN® system, and followed for an average of 9.1 months. All patients achieved fracture healing, and no fracture-related infections, amputations, or reoperations due to infection were reported.

These early findings contribute to the growing body of US clinical evidence supporting CERAMENT G and demonstrate that the outcomes achieved in Europe can be reproduced in a US clinical setting.

Ongoing research

CERTITUDE is a prospective cohort study with three years of follow-up involving 121 patients with bone infection and surgically managed with CERAMENT G. The study is designed to document the long-term safety and clinical effectiveness of the treatment and is part of the post-market regulatory follow-up required following the FDA's De Novo authorization of CERAMENT G. Final reporting to the FDA is expected in 2031.

The French CRIOAc[7] network has initiated CONVICTION, a randomized controlled trial to evaluate the efficacy of CERAMENT G in the treatment of osteomyelitis. The French Ministry of Health has decided to fund the study. A research grant from BONESUPPORT to partially finance the products used in the study, has been awarded.

The study evaluates the effectiveness of CERAMENT G in the treatment of osteomyelitis. The study is a national multicenter study and is being conducted by clinics that are part of the CRIOAc network. The recruitment of patients to the study has been slow and we are in dialogue with participating hospitals and CRIOAc about how the recruitment rate could be accelerated.

A positive outcome of the study would mean that a large commercial opportunity will arise in the French market and that improved reimbursement status is obtained.

CERAMENT FOR FOOT AND ANKLE SURGERY

Diabetes is one of the fastest-growing chronic diseases globally, with more than one in eleven adults currently living with the condition. Approximately 3.2 percent of people with diabetes suffer from infected foot ulcers – a serious condition that often leads to severe complications, bone infection, and increased risk of amputation.

3 Hofmann et al. "Autologous Iliac Bone Graft Compared with Biphasic Hydroxyapatite and Calcium Sulfate Cement for the Treatment of Bone Defects in Tibial Plateau Fractures". The Journal of Bone and Joint Surgery: Volume 102 - Issue 3 - p 179-193. February 2020.
4 McNally M et al. "Mid- to Long-Term Results of Single-Stage Surgery for Patients with Chronic Osteomyelitis Using a Bioabsorbable Gentamicin-Loaded Ceramic Carrier." The Bone & Joint Journal, 104-B.9, 1095–1100. September 2022.
5 Henry et al. "Long-Term Follow-Up of Open Gustilo-Anderson IIIB Fractures Treated with an Adjuvant Local Antibiotic Hydroxyapatite Bio-Composite". Cureus 15(5): e39103. May 2023.
6 Sandilands SM. et al. Intramedullary nailing with absorbable antibiotic-eluting ceramic for fracture-related infection prophylaxis in high-risk open fractures: a case series and technique. OTA International: The Open Access Journal of Orthopaedic Trauma. Volume 9(1), e478. March 2026.
7 CRIOAc (Reference Center for Osteoarticular Infections) is a healthcare network in France that is implemented through a nationwide health ministry program to improve outcomes in the management of bone and joint infections. Awaiting study finalization.

A clinical study by Vasukutty et al.[8], published in The Diabetic Foot Journal, showed that the use of CERAMENT G in combination with surgical debridement resulted in 94 percent of patients avoiding amputation. Data from Australia[9] published in 2024 showed that patients treated with CERAMENT G or CERAMENT V had an amputation rate of only two percent compared to 18 percent in the control group treated with standard care. The number of hospital days was significantly lower in the CERAMENT group; 12.5 days compared to 25.1 for the control group. Metaoy et al.[10] also showed in a recently published study significant clinical benefits of antibiotic-releasing CERAMENT G and CERAMENT V in the treatment of bone infections due to diabetes-related foot ulcers. The study included 105 patients and showed that survival in the CERAMENT group was 87.5 percent compared to only 44.9 percent ($p<0.00001$) for the standard treatment group, measured over five years. Additionally, significant improvements in infection control and reduced risk of reinfection and amputation were noted.

With an estimated global population of 1.3 billion diabetes patients by 2050, according to The Lancet[11], innovative treatment solutions like CERAMENT are crucial to meeting growing healthcare challenges and improving patients' quality of life.

Ongoing research

BONESUPPORT financially supports several physician-initiated studies in this area.

CERAMENT IN ARTHROPLASTY

Periprosthetic joint infection (PJI) is a serious complication following knee and hip prosthesis surgery, with an incidence of approximately 1-2 percent after primary joint replacement surgeries. PJI can lead to severe consequences such as sepsis, prosthesis loosening, and the need for additional surgical interventions. The risk of PJI after a previous revision surgery has an incidence of 7-19 percent and is associated with severe complications. The risk of reinfection after PJI is substantially higher. According to the German Endoprosthesis Register (Endoprothesenregister Deutschland), the risk of recurrent infection following, for example, hip revision surgery is 30 percent within two years.

Logoluso et al.[12] demonstrated as early as 2016 in a prospective study that CERAMENT G can be used in conjunction with two-stage revision of infected hip and knee revisions. Ninety-five percent of patients were infection-free during the average follow-up period of 18 months (12-36 months).

A prospective study[13] (CeraHip) was conducted at Charité – Universitätsmedizin Berlin in Germany to evaluate cementless one-stage hip revision using CERAMENT G for the treatment of bone infection associated with PJI (CeraHip[12]). The study included 20 patients with confirmed PJI and focused on two key aspects: reconstruction of bone defects and local antibiotic treatment with the goal of preventing reinfection. The patient perspective was included through patient-reported outcome measures (PROMs), providing valuable insights into recovery and quality of life.

After an average follow-up of 3.3 years, all patients were free from infection. Radiological examinations after 12 months showed correct implant positioning and good bone integration. PROMs showed significant improvements: the Harris Hip Score increased from 47.7 preoperatively to 80.1 after 12 months ($p<0.001$), and EQ-5D-5L improved from 0.43 to 0.88 during the same period ($p<0.001$).

The results strengthen the evidence base for the use of CERAMENT G as an effective solution in one-stage revisions, with favorable clinical and patient-reported outcomes.

Ongoing research

Planning for CERAhip 2.0 is underway, as are preparations for a randomized multicenter study designed to compare one-stage exchange surgery for periprosthetic joint infection (PJI) of the hip or knee using CERAMENT® G combined with short-course systemic antibiotic therapy, versus treatment without local antibiotic delivery and with prolonged systemic antibiotic therapy.

CERAMENT IN SPINE SURGERY

Each year, approximately 1.5 million instrumented spinal surgeries are performed, including 750,000 Spinal Fusion procedures in the US. In the area of Spinal Fusion, about 20 percent of procedures fail due to insufficient bone formation, and 2-6 percent of the total number of procedures become infected. An infection in the spine can have devastating consequences and often leads to very serious complications, which is why off-label use of local antibiotics is common. Market data indicates that local antibiotics are used in 40 percent of all spinal surgeries.

Ongoing research

During 2026, the Company will continue to build its preclinical evidence base. At the same time, preparations are underway for two clinical studies planned to commence in 2027: a single-center study involving approximately 20 patients to evaluate CERAMENT BVF in spinal fusion, and a larger multicenter study involving approximately 300–400 patients to investigate the efficacy of antibiotic-eluting CERAMENT within the same indication area.

8 Vasukutty et al. "Limb salvage surgery in diabetic foot infection: encouraging early results with a local antibiotic carrier". The Diabetic Foot Journal. 2022;25(2):1–5. August 2022.
9 Chow et al. "Definitive single-stage surgery for treating diabetic foot osteomyelitis: a protocolized pathway including antibiotic bone graft substitute use". ANZ Journal of Surgery, May 2024.
10 Metaoy S, Rusu I & Pillai A. "Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis". Clin Diabetes Endocrinol 10, 51. December 2024.
11 Liane K et al. "Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021". The Lancet, Volume 402, Issue 10397, 203 – 234. July 2023.
12 Logoluso et al. "Calciumbased, antibiotic-loaded bone substitute as an implant coating: a pilot clinical study". J Bone Joint Infect. 2016;1:59-64.
13 Khakzad T. et al. Cementless one-stage hip revision arthroplasty with an injectable antibiotic bone graft substitute. Bone Jt Open. Volume 6(9), 1146-1155. September 2025.

HEALTH ECONOMICS

One of the largest challenges when introducing new and innovative healthcare treatment is to ensure that healthcare systems around the world understand the value of the treatment and include it in the care offered to the patient. BONESUPPORT undertakes a variety of activities to ensure that the Company's products are included in the remuneration systems where our products are marketed.

One of the obvious positive health economic benefits that comes from the clinical benefits CERAMENT offers is a reduced utilization of healthcare resources. A reduced number of re-infections and reduced amputation frequency as a result from treatment with CERAMENT G and CERAMENT V in a one-step procedure, naturally leads to fewer return visits and fewer surgeries. This, in turn, leads to reduced hospital stays. The significance of health benefits and the calculation models for evaluating the cost-effectiveness of health benefits differ between different healthcare systems.

In August 2025, BONESUPPORT was granted New Technology Add-on Payment (NTAP) status for CERAMENT G in the treatment of open fractures, starting October 1. This allows US hospitals to receive increased reimbursement for inpatient procedures involving the product. From January 1, 2024, through December 2026, CERAMENT G is also eligible for Transitional Pass-Through (TPT) payment in outpatient care. Both programs are administered by the Centers for Medicare & Medicaid Services (CMS) and are designed to promote medical innovation and improve access to advanced treatments.

CERAMENT G – A COST EFFICIENT STRATEGY FOR TREATMENT OF BONE INFECTION

In 2022, a cost-benefit analysis was conducted to assess the potential implications for the American healthcare system of transitioning to a single-stage procedure with CERAMENT G. The modelling, which is based on available clinical data as well as cost data from CMS, Centers for Medicare & Medicaid Services, was done in collaboration with national expertise in health economics and clinical orthopedics. The results were presented at the end of 2022, partly at the leading health economic conference ISPOR and partly at the SOMOS conference aimed at orthopedic surgeons. The analysis shows that a one-step procedure with CERAMENT G is a cost-effective strategy for treating bone infection compared to current US healthcare standards. When using CERAMENT G, instead of PMMA beads with antibiotics, the cost reduction is estimated on average to be about SEK 300 thousand (USD 27,943) per patient, over a period of two years, due to fewer surgeries and fewer surgical complications during and after procedures[1]. The analysis also shows improved quality of life for patients. It will be an important tool for communicating the value of CERAMENT G to, among others, private insurance companies.

CERAMENT G OR CERAMENT V LEADS TO REDUCED DAYS OF CARE IN PATIENTS WITH BONE INFECTIONS[2]

The Nuffield Orthopaedic Centre (NOC) has shown that they have been able to reduce the degree of re-infection in osteomyelitis patients by 56 percent compared to their previous standard of treatment. In an analysis involving approximately 25,000 patients who underwent surgical treatment for osteomyelitis in 2013-2017, the patient group treated at NOC after the introduction of CERAMENT G or CERAMENT V in a one-step procedure was compared with patients cared for at other hospitals in England. The results presented in The Journal of Bone and Joint Infection showed that CERAMENT G or CERAMENT V in a one-step procedure contributed to significantly improved patient outcomes. The hospital stay, in connection with osteomyelitis surgery and the following two years, were on average 16 days shorter for the group that received CERAMENT G and CERAMENT V at NOC. In addition, patients at NOC had a significantly lower risk of amputation (6.47 percent) compared to the Rest of England control group (12.71 percent). With the addition of CERAMENT G or CERAMENT V in the treatment of osteomyelitis, the total saving in the number of days of care associated with surgery and subsequent care, could amount to approximately

Progress in the quarter

CMS in the US has proposed improved reimbursement for CERAMENT G in complex orthopedic infection surgery. The final decision is expected at the end of the summer.

1 Carter, M et al. "EE240 Does Single Stage Surgery of Long Bone Infection Using Gentamicin-Eluting Bone-Graft Substitutes Result in Decreased Cost and Improved Quality of Life Compared to Traditional Approaches?" Value in Health 25.12 (2022): S100.

2 Ferguson, J et al. "A retrospective cohort study comparing clinical outcomes and healthcare resource utilisation in patients undergoing surgery for osteomyelitis in England: a case for reorganising orthopaedic infection services", J. Bone Joint Infect., 2021 Apr 28;6(5), 151–163.

GBP 44 million annually, calculated on 6,250 treated patients per year.

REDUCED RISK OF DEEP INFECTIONS WITH CERAMENT G AND CERAMENT V

Another area where CERAMENT G and CERAMENT V can help reduce healthcare costs is in the treatment of serious trauma fractures. Open tibial fractures represent about 15 percent[3] of all tibial fractures and have a high incidence of infection, with no bone healing as a result. Bone infections often lead to great suffering for the patient and very high healthcare costs. In a Belgian study by Hoekstra et al.[3] of 358 patients, the cost of tibial fractures was studied. The study showed that healthcare costs for patients affected by a deep infection were on average five times higher than for those who did not get an infection, resulting in the cost of treatment increasing from EUR 9,500 to EUR 48,700. A recently published retrospective study from the Netherlands by Haidari et al.[4] points in the same direction. The study examined how the occurrence of fracture-related infections (FRI) in patients with severe bone fractures affects direct hospital costs. A total of 246 patients were included in the study, and 18.3 percent were diagnosed with FRI. A single occurrence of FRI tripled the direct hospital costs, while recurrent infection could result in sevenfold increased costs. The main reasons for the increased costs were longer hospital stays, more surgical procedures, and prolonged intravenous antibiotic treatment. The average cost of treating this type of trauma was EUR 25,000. There are a number of studies that show that CERAMENT contributes to cost-effective care by reducing the number of deep infections. One of these is a study by Henry et al.[5] on 81 patients with severe open tibial fractures treated with CERAMENT G in a one-step procedure. In the study, with a mean follow up time of 55.5 months, three patients (3.7 percent) suffered from a deep infection compared with historical references of up to 52 percent incidence of infection. This shows that one-step treatment with antibiotic-eluting CERAMENT for open tibial fractures can effectively reduce the incidence of cost-driving infections.

3 Hoekstra et al. "Economics of open tibial fractures: the pivotal role of length-of-stay and infection". Health Econ Rev 2017; 7:32.
4 Haidari, S et al. "Costs of fracture-related infection: the impact on direct hospital costs and healthcare utilization". European Journal of Trauma and Emergency Surgery. 09 April 2024 doi: 10.1007/s00068-024-02497-9
5 Henry, Joshua A et al. "Long-Term Follow-Up of Open Gustilo-Anderson IIIB Fractures Treated with an Adjuvant Local Antibiotic Hydroxyapatite Bio-Composite." Cureus vol. 15,5 e39103. 16 May. 2023, doi:10.7759/cureus.39103.

GLOSSARY

Allograft. The bone graft transplanted between genetically non-identical individuals of the same species. Allograft can be living related (harvested from femoral heads during hip arthroplasty) or cadaveric.

Arm/Study arm. A group of study participants characterized by the intervention or treatment regimen they receive in a clinical trial.

Arthroplasty. A surgical procedure aimed at restoring the function of a damaged or diseased joint, most commonly by replacing it with an artificial joint – known as a prosthesis.

Autograft. A bone graft harvested from the patient's own skeleton, usually from the iliac crests.

Bisphosphonate. A group of medicines that inhibit bone breakdown.

BMA. Bone Marrow Aspirate.

BMP. Bone Morphogenic Protein.

Bone cement. Binders used to attach prostheses to bone or glue bone, often in the form of a hardening plastic, polymethyl acrylate (PMMA), or Calcium Phosphate.

Bone graft substitute. A synthetic material used as bone grafts instead of biological bone tissue.

CERAMENT BVF. CERAMENT BONE VOID FILLER.

CERAMENT G. CERAMENT with Gentamicin.

CERAMENT V. CERAMENT with Vancomycin.

CERTiFy. A prospective, randomized, controlled clinical trial with 135 patients in 20 leading trauma centers in Germany, aimed to compare treatment of CERAMENT BVF with autologous bone graft (autograft) transplantation.

Clinical study. A study on humans of e.g. a medical device or a pharmaceutical product.

CMS (The Centers for Medicare and Medicaid Services). CMS provides health coverage to more than 100 million people through Medicare, Medicaid, the Children's Health Insurance Program, and the Health Insurance Marketplace.

CONVICTION. A randomized, controlled trial to evaluate the efficacy of CERAMENT G in the treatment of osteomyelitis (chronic bone infection).

CRIOAc. A healthcare network in France that is implemented through a nationwide health ministry program to improve outcomes in the management of bone and joint infections.

C-shares. Performance shares within performance share programs issued in the form of class C-shares.

DBM (Demineralized Bone Matrix). A processed form of allograft, an acid-extracted matrix from human bone sources.

De Novo. A regulatory pathway at the FDA for low to moderate risk medical devices that have no existing predicate on the market.

FDA (US Food and Drug Administration). The federal medical authority in the US.

GPO (Group Purchasing Organization). An entity with the purpose of realizing savings and efficiencies by aggregating purchasing volumes.

Health economics. Analyzing costs and effects within healthcare and other sectors that work with health related issues. The goal is to provide a basis for well founded priorities so that society's resources are used in the best possible way.

Hematoma. A localized collection of blood outside the blood vessels.

HEOR (Health Economics and Outcomes Research). Scientific discipline that quantifies the economic and clinical outcomes of medical technology.

HTA (Health Technology Assessment). Systematic evaluation of the relative safety, efficacy and cost-effectiveness of a treatment in comparison to current treatment alternatives.

ICUR (Incremental Cost-Utility Ratio). A quote that compares cost and utility between two alternative treatment alternatives.

IDN (Integrated Delivery Network). An integrated delivery network, also referred to as a health system, is an organization that owns and operates a network of healthcare facilities.

Indication. Reasons underlying the action taken; an expression used to describe the conditions under which a medicine or a medical technology device may be used.

LTM. Latest twelve months.

MDR (the Medical Device Regulation). An EU regulation designed to ensure the safety and performance of medical devices.

Micro-CT (Micro-Computed Tomography). Uses X-ray scanning to recreate a 3D-model without destroying the object.

NTAP (New Technology Add-on Payment designation). An additional reimbursement that manufacturers of new, groundbreaking technologies can apply for.

Osteoclasts. Large multinucleated cells involved in bone resorption (breakdown of bone tissue).

Osteoinduction. Osteoinduction at bone graft material (or a growth factor) can stimulate the differentiation of osteoblasts, forming new bone tissues.

Osteomyelitis. A bacterial infection affecting bones.

Osteoporosis. A condition in which bone mass decreases and bone tissue becomes thinner and more porous, leading to weaker bones that are more prone to fractures.

PJI (Periprosthetic Joint Infection). A serious complication following knee and hip replacement surgery.

PMA (Pre-Market Approval). Market pre-approval from the FDA in the US for class III medical devices.

PMMA (Poly Methyl Methacrylate). Often called "bone cement".

Preclinical research. Basic experimental research at the molecular, cellular, and integrative level concerning the life processes that determine the function of the body.

Revision arthroplasty. A follow-up surgical procedure in which a previously performed joint replacement is corrected, replaced, or improved.

SOLARIO. A randomized, European multicenter study showing that orthopedic infections treated surgically with local antibiotic bone defect fillers could reduce systemic antibiotics to less than seven days vs previous standard of care of at least four weeks.

Tibial plateau fracture. Fracture of the upper part of the tibia.

Toxicity. The degree to which substance (a toxin or poison) can harm humans or animals.

TPT (Transitional Pass-Through). Transitional pass-through payments provide additional payment for new devices, drugs, and biologicals that met eligibility criteria for a period of at least two years but not more than three years.

PRESENTATION OF INTERIM REPORT JANUARY – JUNE 2026

The Company invites investors, analysts and media to a web conference (in English) on July 16, 2026 at 10.00 CEST, where CEO Torbjörn Sköld and CFO Håkan Johansson will present and comment on the report and also answer questions. The report will be available on BONESUPPORT's website from 08.00 CEST on the same day and the presentation from the webcast will be uploaded during the day on July 16, 2026. For further details regarding participation, see the investor pages at www.bonesupport.com

FORWARD-LOOKING STATEMENTS

The report contains certain forward-looking information that reflects BONESUPPORT's current views of future events and financial and operational performance. Words such as "intends", "anticipates", "expects", "can", "plans", "estimates" and similar expressions regarding indications or forecasts of future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it is dependent on future events and circumstances.

Forward-looking information is not a guarantee of future results or developments and actual results may differ materially from results referred to in forward-looking information. Forward-looking information in the report is only applicable on the date of issue of the report. BONESUPPORT does not commit to publishing updates or revision of any forward-looking statements as a result of new information, future events or similar circumstances other than those required by applicable legislation.

CONTACT INFORMATION

Torbjörn Sköld, CEO
T: +46 46 286 53 70

Håkan Johansson, CFO
T: +46 46 286 53 70

E: ir@bonesupport.com
www.bonesupport.com

OUR SOUL & OUR HEART

MISSION

Restoring health to improve the quality of life for patients with bone disorders

BONESUPPORT's unique product technology has properties with the potential to revolutionize the care of patients with bone disorders by enabling faster rehabilitation, limiting the number of surgical procedures and reducing the risk of severe infections. The most common procedures consist of bone disorders where the body is unable to perform natural healing and single-stage surgery in connection with bone infection. For patients, surgical treatment including CERAMENT means that they can return to a more normal life more quickly.

VISION

Becoming a global orthobiologics leader

BONESUPPORT's unique technology means that over time, the Company's injectable bio-ceramic bone graft substitutes remodel to natural bones and have the ability to elute drugs. This enables new treatment standards in the treatment of bone diseases/skeletal injuries.

BONESUPPORT's objective during 2026 is a growth in net sales of over 35 percent, in constant exchange rates.

STRATEGY

The strategy is based on three pillars:

Innovation – BONESUPPORT has the market's most innovative solution for the treatment of bone disorders.

Clinical and Health Economic Evidence – The evidence for the CERAMENT platform continues to grow and now amounts to more than 350 publications and abstracts.

Effective commercial platform – BONESUPPORT's commercial and medical organization provides healthcare with products, information, service, training and evidence.

ABOUT BONESUPPORT

BONESUPPORT HOLDING AB (publ), corp. ID 556802-2171, based in Lund, Sweden, is the Parent Company of BONESUPPORT AB who in turn is the Parent Company of the wholly owned subsidiaries in Austria, Denmark, Germany, Italy, the Netherlands, Norway, Spain, Sweden, Switzerland, the UK, and the US. BONESUPPORT is a rapidly growing orthobiologics company that primarily targets the major orthopedic markets in the US and Europe. BONESUPPORT was founded in 1999.

The Company is not aware of any other commercially available products with the same properties as CERAMENT G and CERAMENT V, i.e. an injectable antibiotic-eluting bone graft substitute with proven rapid remodeling into host bone. CERAMENT products are protected by patents, CERAMENT is a registered trademark of BONESUPPORT AB.

BONESUPPORT has well-documented safety and efficacy experience and estimates, based on sales data, that until the beginning of July 2026, 200,000 treatments have been performed with its products worldwide. There is great market potential in the surgical segments Trauma, Foot and Ankle, Revision Arthroplasty and Spinal Surgery, primarily with regard to preventing and treating infections in the extremities and spine.

The CERAMENT portfolio is currently commercially available in the largest European markets, as well as in a number of markets outside Europe. In addition, CERAMENT BVF and CERAMENT G are commercially available in the United States.